QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 why-senestech-shares-are-trading-lower-by-around-50-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Shares of SenesTech, Inc. (NASDAQ: SNES) shares moved lower during Tuesday’s session after the company reported pricing of $5....

 why-springworks-shares-are-trading-higher-by-around-14-here-are-20-stocks-moving-premarket

Shares of SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) surged in pre-market trading after the company reported the FDA approv...

 why-cohbar-cwbr-stock-is-down-nearly-50-today

CohBar Inc (NASDAQ: CWBR) shares are trading lower by 47% to $0.92 Wednesday afternoon.

 why-extreme-networks-shares-are-trading-lower-by-around-15-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Gainers

 cohbar-says-it-intends-to-commence-process-of-liquidating-and-dissolving-itself-in-accordance-with-its-organizational-documents-and-applicable-law

-SEC 8K Filing

 cohbar-says-on-nov-1-got-termination-notice-from-morphogenesis-effective-nov-1-and-merger-agreement-was-terminated-in-accordance-with-terms

-SEC 8K Filing

 cohbar-says-on-oct-31-board-determined-there-was-not-viable-path-forward-to-consummate-merger-primarily-due-to-oral-guidance-received-from-nasdaq

-SEC 8K Filing

 why-faraday-future-intelligent-electric-shares-are-trading-higher-by-around-8-here-are-20-stocks-moving-premarket

Gainers

 cohbar-q2-eps-149-down-from-090-yoy

CohBar (NASDAQ:CWBR) reported quarterly losses of $(1.49) per share. This is a 65.56 percent decrease over losses of $(0.90) pe...

 cohbar-has-received-a-notice-of-allowance-for-its-us-patent-application-titled-therapeutic-peptides-for-the-treatment-of-metabolic-disease-cancer-liver-disease-and-methods-of-modulating-fatty-acid-metabolism

https://patentcenter.uspto.gov/applications/17717982/ifw/docs

 morphogenesis-and-cohbar-announce-results-from-phase-1b-trial-of-ifx-hu20-a-novel-personalized-cancer-vaccine-in-checkpoint-inhibitor-resistant-advanced-merkel-cell-carcinoma-mcc-and-cutaneous-squamous-cell-carcinoma-cscc

Morphogenesis, Inc. ("Morphogenesis"), a privately-held Phase 2/3 clinical-stage biotechnology company developing novel...

 morphogenesis-cohbar-announce-acceptance-of-abstract-for-poster-presentation-at-2023-asco-meeting

Details of the presentation are as follows:Title: Phase 1b trial of IFx-Hu2.0, a novel personalized cancer vaccine, in checkpoi...

 why-americas-car-mart-shares-are-trading-lower-by-12-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Gainers Minerva Surgical, Inc. (NASDAQ: UTRS) shares jumped 209.1% to $0.5622 after the United States Patent and Trademark ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION